Research graph
References from Differentiating poor prognosis from treatment-related fluctuations in Guillain-Barré syndrome for repeating immunoglobulin treatment: an illustrative case report. Local targets link to admitted publications; unresolved targets remain external evidence.
Guillain–Barré syndrome: a comprehensive review
10.1111/ene.16365 · 2024 · External reference
Guillain-Barré syndrome
10.1055/s-2008-1062261 · 2008 · External reference
Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria
10.1093/brain/awt285 · 2014 · External reference
Guillain–Barré Syndrome following Primary Cytomegalovirus Infection: a prospective cohort study
10.1093/cid/cir074 · 2011 · External reference
Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis
10.1016/j.ensci.2023.100468 · 2023 · External reference
Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence
10.1590/0004-282x-anp-2021-0226 · 2022 · External reference
Clinical features of Guillain-Barré syndrome patients with elevated serum creatine kinase levels
10.1186/s12883-020-01796-z · 2020 · External reference
Flaccid quadriparesis with raised creatine kinase in Guillain-Barré syndrome: a case report with review of literature
10.18700/jnc.210011 · 2021 · External reference
Ganciclovir-induced psychosis
10.1056/nejm199610313351814 · 1996 · External reference
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome
10.1111/ene.16073 · 2023 · External reference
Diagnosis and management of Guillain-Barré syndrome in ten steps
10.1038/s41582-019-0250-9 · 2019 · External reference
Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the ninth special issue
10.1002/jca.22043 · 2023 · External reference
Guillain-barré syndrome
10.1016/s0140-6736(21)00517-1 · 2021 · External reference
Plasma exchange following immunoglobulins for Guillain-Barré-Syndrome: a persisting problematic practice
10.3389/fneur.2025.1712202 · 2026 · External reference
Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy
10.1016/j.transci.2020.102993 · 2020 · External reference
First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19
10.1186/s13054-020-03070-7 · 2020 · External reference
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial
10.1016/s1474-4422(20)30494-4 · 2021 · External reference
Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations
10.1212/01.wnl.0000167549.09664.b8 · 2005 · External reference
Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange
10.1136/jnnp.54.11.957 · 1991 · External reference
Treatment-related fluctuations in Guillain Barré syndrome and the conundrum of additional cycles of plasmapheresis
10.4103/aian.aian_242_17 · 2017 · External reference
